Alberta's NMS Program Summary

Who

Alberta's Newborn Metabolic Screening (NMS) Program is a population-based screening program delivered by Alberta Health Services (AHS) in partnership with Alberta Health, Health Canada – First Nations Inuit Health Branch (FNIHB) Alberta Region, physicians and midwives, and parents and guardians. The NMS Program is coordinated by a dedicated team within AHS Population Public & Indigenous Health (PPIH).

What and Why

The NMS Program screens for 17 treatable conditions (14 metabolic conditions, 2 endocrine conditions and cystic fibrosis [CF]) to identify and treat infants with any of the screened conditions as early as possible. By informing parents and guardians, health professionals and the public about the NMS Program, the NMS Program is able to achieve the NMS Program is able to achieve its goals of minimizing morbidity and mortality of Alberta infants through early detection and treatment of screened conditions; and ensuring that all infants born in Alberta receive timely access to effective newborn blood spot screening and have an initial screen result reported within 10 days of age.

How

Service delivery within the NMS Program is supported along the newborn blood spot screening pathway by many providers within AHS, Calgary Laboratory Services (CLS), Dyna**LIFE**DX, Covenant Health, FNIHB, physicians and midwives.



For more information, contact
nmsprogram@ahs.ca

Alberta Health Services
Newborn Metabolic Screening

The NMS Program's quality management framework (QMF) provides an operational model to manage population-based screening and achieve continuous quality improvement along the newborn blood spot screening pathway. The purpose of the NMS Program's QMF is to maximize screening opportunities, minimize potential errors and reduce the risk of missing a newborn, screen, result and or follow-up.



Current State

In 2016-2017

- 99.46% (54,891/55190) of registered infants received an initial newborn blood spot screen
- 99.22% (54,465/54,891) of registered screened infants had a screen result reported within 10 days of age
- 0.49% (271/54,960) of screened infants received abnormal screen results (250 critical results and 21 double borderline results) requiring clinical follow-up
- 67 screened infants received abnormal diagnostic outcomes
- 1.94% (1,129/58,158) of samples received by the NMS Lab were determined to be inadequate

Source: AHS Provincial Newborn Metabolic Screening Program Report 2016-2017